CD81/TSPAN28 recombinant proteins and antibodies

CD81, also known as TSPAN28, is a tetraspanin family transmembrane protein, widely expressed on the surface of various cell types, particularly immune cells such as B cells, T cells, and dendritic cells, as well as hepatocytes. As an important immune regulatory molecule, CD81 plays a key role in cell-cell interactions, signal transduction, and immune responses. CD81 regulates cell migration, adhesion, and immune reactions by forming complexes with other tetraspanins and co-receptors, and is crucial in processes such as B cell receptor (BCR) signaling and hepatitis virus infections.

CD81 plays a significant role in hepatitis virus (especially Hepatitis C Virus, HCV) infection, acting as one of the core receptors for HCV entry into host cells. HCV enters hepatocytes by binding to CD81, facilitating viral replication and spread. Additionally, CD81 is involved in immune system regulation, particularly in T cell activation and immune tolerance. Therefore, CD81 holds great research value in areas such as immune diseases, liver diseases, and cancer.
Currently, research targeting CD81 primarily focuses on its role in viral infections, tumor immune evasion, and immune regulation. Ongoing drug development targeting CD81 includes monoclonal antibodies, vaccines, and small molecule inhibitors. For example, monoclonal antibodies targeting CD81 can block the interaction between HCV and CD81, effectively inhibiting viral infection. Additionally, certain small molecules are being studied to inhibit CD81’s role in hepatitis virus infection and immune regulation, offering new therapeutic strategies for treating diseases like hepatitis C.

Several pharmaceutical companies have entered the field of CD81-targeted research, particularly in viral infections and immunotherapy. Leading pharmaceutical companies such as Gilead, Merck, and Sanofi have made progress in the development of CD81-targeted drugs. In particular, CD81-targeted therapies hold promise for providing new treatment options for patients with hepatitis C. These companies aim to improve the efficacy of existing treatments and offer more therapeutic choices for patients, especially in cases where there is resistance to current therapies.

To assist in the development of CD81 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CD81 targets. Products include active CD81 recombinant proteins, full-length CD81 proteins, CD81 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CD81 biotherapy, DIMA BIOTECH has also prepared a CD81 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD81 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.